news

Licensing agreement deals decline in rare diseases space, says report

3
SHARES

New research has shown that complex collaborations and partnerships are increasing, while licensing agreements are decreasing in the rare disease space.

Licensing agreement for rare disease

According to a newly released report, licensing agreements are decreasing in the rare disease space in favour of more complex collaborations and partnerships. Conducted by Globaldata, the research revealed that of the strategic alliances formed by the top 10 biopharma and pharma companies (by market cap) in the last year, only 17 percent were in the rare diseases space.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Madeleine Roche, Associate Analyst at GlobalData commented: “The recent partnership deal between pharmaceutical giant Takeda Pharmaceutical Co and private biotech Evox Therapeutics, completed in March 2020 and valued at $882 million, is an example of how big pharma companies are searching for innovative biotechs to invest in the rare diseases space.”

Licensing agreements

“An emerging trend towards early stage rare disease deals – as noted by Jazz Parmaceuticals’ Executive Vice-President Robert Lannone at the BIO 2020 conference last month – has been highlighted by high-profile partnerships such as the co-development deal between Gilead Sciences and Galapagos NV in August 2019, valued at over $6.5 million,” Roche continued. 

Data from the GlobalData Pharmaceutical Intelligence Center Deals Database also support this, highlights the report. The outlet says its data shows that licensing agreements in the rare diseases space have decreased by 40 percent over the last five years.

Share via
Share via